| Objective To investigate the association between MDM2 polymorphism and susceptibility of esophageal carcinoma and gastric carcinoma. Methods We use PubMed, Embase, CNKI, Wanfang and the VIP database to search the articles which focused on the association between MDM2 polymorphism and esophageal squamous cell carcinoma or gastric carcinoma. The study design of the article was case-control study. Pooled results were showed by the odds ratio (OR) and 95% confidence interval (CI). Results Meta-analysis showed that：Dominant genotype (TT、TG) of MDM2 can reduce the risk of the esophageal squamous cell carcinoma or gastric cancer, TT+TG vs GG：OR=0.73, 95%CI=(0.59, 0.91), P<0.001. Compared with mutant homozygote (GG), wild homozygote(TT) could reduce the risk of the esophageal squamous cell carcinoma and gastric cancer, TT vs GG: esophageal squamous cell carcinoma OR=0.79, 95%CI= (0.68, 0.93), P=0.005; gastric cancer OR=0.52, 95%CI= (0.38, 0.72), P<0.001; mutant heterozygote(TG) could only reduce the risk of the gastric cancer, TG vs GG: esophageal squamous cell carcinoma OR=0.74, 95%CI=(0.48, 1.14), P=0.173; gastric cancer OR=0.62, 95%CI=(0.50, 0.75), P<0.001. However, there was no statistical significance in TT vs TG: esophageal squamous cell carcinoma OR=1.01, 95%CI= (0.80, 1.27), P=0.966; gastric cancer OR=0.85, 95%CI= (0.67, 1.08), P=0.193. Conclusion The MDM2 genic polymorphism may be impact the risk of esophageal squamous cell carcinoma and gastric cancer. Dominant genes (TT、TG) can reduce the risk of the esophageal squamous cell carcinoma and gastric cancer. |
